Pancreatic cancer jab sparks immune response but misses trial goal

An off-the-shelf KRAS vaccine raised T-cell responses in 89 of 90 tested patients, Mayo Clinic said, but its phase 2 trial missed its main goal. Patients stayed cancer-free for a median 23.8 months on the vaccine versus 21.2 months without it, not a significant gap. Maker Elicio said in June a phase 3 trial was subject to financing.